Information about Geographic Areas

9 Months Ended

Sep. 30, 2018

The Company operates as a single reportable segment and enables customers to perform both research and clinical testing on its nCounter Analysis Systems. The Company has one sales force that sells these systems to both research and clinical testing labs, and its nCounter Elements reagents can be used for both research and diagnostic testing. In addition, the Company’s Prosigna Breast Cancer Assay is marketed to clinical laboratories.

The following table of total revenue is based on the geographic location of distributors or end users who purchase products and services and collaborators. For sales to distributors, their geographic location may be different from the geographic locations of the ultimate end user. For collaboration agreements, revenues are derived from partners located primarily in the United States. Americas consists of the United States, Canada, Mexico and South America; and Asia Pacific includes Japan, China, South Korea, Singapore, Malaysia, India and Australia. Revenue by geography was as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Americas	$	21,032	$	20,060	$	53,865	$	59,612
Europe & Middle East	6,110		4,911		18,260		14,564
Asia Pacific	1,474		2,045		4,575		5,496
Total revenue	$	28,616	$	27,016	$	76,700	$	79,672

Total revenue in the United States was $20.4 million and $19.7 million for the three months ended September 30, 2018 and 2017, respectively, and $51.2 million and $58.3 million for the nine months ended September 30, 2018 and 2017, respectively. The Company’s assets are primarily located in the United States and not allocated to any specific geographic region. Substantially all of the Company’s long-lived assets are located in the United States.